WO2010138426A1 - Composition for use in decreasing the transmission of human pathogens - Google Patents
Composition for use in decreasing the transmission of human pathogens Download PDFInfo
- Publication number
- WO2010138426A1 WO2010138426A1 PCT/US2010/035864 US2010035864W WO2010138426A1 WO 2010138426 A1 WO2010138426 A1 WO 2010138426A1 US 2010035864 W US2010035864 W US 2010035864W WO 2010138426 A1 WO2010138426 A1 WO 2010138426A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- facial mask
- composition
- fabric
- layer
- flap
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 133
- 244000052637 human pathogen Species 0.000 title claims abstract description 93
- 230000005540 biological transmission Effects 0.000 title claims abstract description 61
- 230000003247 decreasing effect Effects 0.000 title claims abstract description 40
- 239000004744 fabric Substances 0.000 claims abstract description 297
- -1 polypropylene Polymers 0.000 claims abstract description 225
- 239000004743 Polypropylene Substances 0.000 claims abstract description 186
- 229920001155 polypropylene Polymers 0.000 claims abstract description 186
- 239000000463 material Substances 0.000 claims abstract description 145
- 239000011248 coating agent Substances 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 22
- 230000001815 facial effect Effects 0.000 claims description 181
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 138
- 239000000835 fiber Substances 0.000 claims description 115
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 54
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 38
- 239000004246 zinc acetate Substances 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 35
- 230000000840 anti-viral effect Effects 0.000 claims description 33
- 230000000844 anti-bacterial effect Effects 0.000 claims description 30
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 28
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 28
- 230000007423 decrease Effects 0.000 claims description 28
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 27
- 239000000985 reactive dye Substances 0.000 claims description 23
- 230000000843 anti-fungal effect Effects 0.000 claims description 22
- 229940121375 antifungal agent Drugs 0.000 claims description 22
- 239000002736 nonionic surfactant Substances 0.000 claims description 20
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 19
- 150000001455 metallic ions Chemical class 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 8
- 239000005751 Copper oxide Substances 0.000 claims description 8
- 229910000431 copper oxide Inorganic materials 0.000 claims description 8
- 230000000855 fungicidal effect Effects 0.000 claims description 8
- 230000003253 viricidal effect Effects 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 description 89
- 230000027455 binding Effects 0.000 description 87
- 229920000297 Rayon Polymers 0.000 description 63
- 239000002964 rayon Substances 0.000 description 62
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 42
- 241000700605 Viruses Species 0.000 description 37
- 229920002678 cellulose Polymers 0.000 description 35
- 239000001913 cellulose Substances 0.000 description 35
- 235000015165 citric acid Nutrition 0.000 description 35
- 239000000975 dye Substances 0.000 description 33
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 31
- 239000002245 particle Substances 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 230000002458 infectious effect Effects 0.000 description 24
- WXQMFIJLJLLQIS-UHFFFAOYSA-N reactive blue 21 Chemical compound [Cu+2].C1=CC(S(=O)(=O)CCO)=CC=C1NS(=O)(=O)C1=CC=C2C([N-]3)=NC(C=4C5=CC=C(C=4)S(O)(=O)=O)=NC5=NC(C=4C5=CC=C(C=4)S(O)(=O)=O)=NC5=NC([N-]4)=C(C=C(C=C5)S(O)(=O)=O)C5=C4N=C3C2=C1 WXQMFIJLJLLQIS-UHFFFAOYSA-N 0.000 description 24
- 238000005670 sulfation reaction Methods 0.000 description 23
- 230000019635 sulfation Effects 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000001717 pathogenic effect Effects 0.000 description 17
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 15
- 239000010949 copper Substances 0.000 description 15
- 229910052802 copper Inorganic materials 0.000 description 15
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- 229910052725 zinc Inorganic materials 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 241000700584 Simplexvirus Species 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 8
- 206010057190 Respiratory tract infections Diseases 0.000 description 8
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 229920003043 Cellulose fiber Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000003466 welding Methods 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 201000009240 nasopharyngitis Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010039083 rhinitis Diseases 0.000 description 5
- 125000005629 sialic acid group Chemical group 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001180 sulfating effect Effects 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 229920001131 Pulp (paper) Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 238000006277 sulfonation reaction Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- MCNLTUITFWBDSX-UHFFFAOYSA-N 4-chlorotriazin-5-amine Chemical compound NC1=CN=NN=C1Cl MCNLTUITFWBDSX-UHFFFAOYSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000004677 spark ionization mass spectrometry Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- BLFZMXOCPASACY-UHFFFAOYSA-N 1,4-bis(propan-2-ylamino)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NC(C)C)=CC=C2NC(C)C BLFZMXOCPASACY-UHFFFAOYSA-N 0.000 description 1
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 1
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 1
- IVIDDMGBRCPGLJ-UHFFFAOYSA-N 2,3-bis(oxiran-2-ylmethoxy)propan-1-ol Chemical compound C1OC1COC(CO)COCC1CO1 IVIDDMGBRCPGLJ-UHFFFAOYSA-N 0.000 description 1
- SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 1
- SEFYJVFBMNOLBK-UHFFFAOYSA-N 2-[2-[2-(oxiran-2-ylmethoxy)ethoxy]ethoxymethyl]oxirane Chemical compound C1OC1COCCOCCOCC1CO1 SEFYJVFBMNOLBK-UHFFFAOYSA-N 0.000 description 1
- SUPFNMXTAGSTIP-UHFFFAOYSA-N 2-chloro-4,6-difluoropyrimidine Chemical compound FC1=CC(F)=NC(Cl)=N1 SUPFNMXTAGSTIP-UHFFFAOYSA-N 0.000 description 1
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- JJEKTVIORQZIJU-UHFFFAOYSA-N 4-fluorotriazin-5-amine Chemical compound NC1=CN=NN=C1F JJEKTVIORQZIJU-UHFFFAOYSA-N 0.000 description 1
- OECTYKWYRCHAKR-UHFFFAOYSA-N 4-vinylcyclohexene dioxide Chemical compound C1OC1C1CC2OC2CC1 OECTYKWYRCHAKR-UHFFFAOYSA-N 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229910000639 Spring steel Inorganic materials 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical class OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- XWZDJOJCYUSIEY-UHFFFAOYSA-L disodium 5-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].Oc1c(N=Nc2ccccc2)c(cc2cc(cc(Nc3nc(Cl)nc(Cl)n3)c12)S([O-])(=O)=O)S([O-])(=O)=O XWZDJOJCYUSIEY-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical class [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000001007 phthalocyanine dye Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- DHHGSXPASZBLGC-VPMNAVQSSA-L remazole orange-3R Chemical compound [Na+].[Na+].OC=1C2=CC(NC(=O)C)=CC=C2C=C(S([O-])(=O)=O)C=1\N=N\C1=CC=C(S(=O)(=O)CCOS([O-])(=O)=O)C=C1 DHHGSXPASZBLGC-VPMNAVQSSA-L 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YQEHHPFEQLDFCN-UHFFFAOYSA-K trisodium 5-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-hydroxy-3-[(2-sulfonatophenyl)diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].Oc1c(N=Nc2ccccc2S([O-])(=O)=O)c(cc2cc(cc(Nc3nc(Cl)nc(Cl)n3)c12)S([O-])(=O)=O)S([O-])(=O)=O YQEHHPFEQLDFCN-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D129/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Coating compositions based on hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Coating compositions based on derivatives of such polymers
- C09D129/02—Homopolymers or copolymers of unsaturated alcohols
- C09D129/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
- A01N59/20—Copper
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1107—Protective face masks, e.g. for surgical use, or for use in foul atmospheres characterised by their shape
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
- A62B18/00—Breathing masks or helmets, e.g. affording protection against chemical agents or for use at high altitudes or incorporating a pump or compressor for reducing the inhalation effort
- A62B18/02—Masks
- A62B18/025—Halfmasks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
- B32B5/02—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by structural features of a fibrous or filamentary layer
- B32B5/022—Non-woven fabric
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
- B32B5/22—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by the presence of two or more layers which are next to each other and are fibrous, filamentary, formed of particles or foamed
- B32B5/24—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by the presence of two or more layers which are next to each other and are fibrous, filamentary, formed of particles or foamed one layer being a fibrous or filamentary layer
- B32B5/26—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by the presence of two or more layers which are next to each other and are fibrous, filamentary, formed of particles or foamed one layer being a fibrous or filamentary layer another layer next to it also being fibrous or filamentary
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
- A62B23/00—Filters for breathing-protection purposes
- A62B23/02—Filters for breathing-protection purposes for respirators
- A62B23/025—Filters for breathing-protection purposes for respirators the filter having substantially the shape of a mask
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/02—Coating on the layer surface on fibrous or filamentary layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/26—Polymeric coating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2262/00—Composition or structural features of fibres which form a fibrous or filamentary layer or are present as additives
- B32B2262/02—Synthetic macromolecular fibres
- B32B2262/0253—Polyolefin fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/714—Inert, i.e. inert to chemical degradation, corrosion
- B32B2307/7145—Rot proof, resistant to bacteria, mildew, mould, fungi
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2437/00—Clothing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2535/00—Medical equipment, e.g. bandage, prostheses or catheter
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
- C08K5/0058—Biocides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
- C08K5/092—Polycarboxylic acids
Definitions
- infectious human diseases such as human respiratory tract infections
- viral causes of infectious human diseases include: Influenza A virus (including 'swine flu' such as the 2009 HlNl strain); Influenza B-C virus (coryza; 'common cold'); Human adenovirus A-C (various respiratory tract infections; pneumonia); Human Para-influenza virus (coryza; 'common cold;' croup); Mumps virus (epidemic parotitis); Rubeola virus (measles); Rubella virus (German measles); Human respiratory syncytial virus (RSV) (coryza; 'common cold'); Human coronavirus (SARS virus) (SARS); Human rhinovirus A-B (coryza; 'common cold'); parvovirus B19 (fifth disease); variola virus (smallpox); varicella-zoster virus (
- influenza viruses worldwide infect an estimated 3 million to 5 million people, and kill between 250,000 to 500,000 people each year.
- cyclical influenza virus pandemics occur, such as the influenza outbreak in 1918 which killed between 20 million and 50 million people worldwide.
- Protective facial masks are designed to be worn by both the infected person to prevent transmission of infection, and by the non-infected person to prevent being infected.
- facial masks In order to keep the costs of production reasonable, facial masks generally are produced in only a few sizes or only one size.
- facial masks have been designed to incorporate mechanical structures, such as elastic bands that loop around the ears to seal the facial mask against the face of the wearer by increasing the force that holds the facial mask in place, thereby deforming the perimeter of the facial mask to more tightly fit the face of the wearer. While mitigating the problem, these mechanical structures create an unpleasant sensation of pressure for the wearer over time, and tend to limit the period that the facial mask can be worn. This is especially true for children who have a lower tolerance of discomfort. Additionally, conventional facial masks do not inactivate a substantial portion of the infectious particles that ingress between the facial mask and the face of the wearer.
- a composition for coating a polypropylene-based fabric or polypropylene-based material such as for example a fabric or a material for use in decreasing the transmission of human pathogens.
- the composition comprises an aqueous solution of citric acid, polyvinyl alcohol and one or more than one nonionic surfactant.
- the polyvinyl alcohol is partially hydrolyzed.
- the composition comprises between 0.5% to 4% citric acid and between 0.5% and 4% polyvinyl alcohol.
- the composition comprises between 1 % to 3 % citric acid and between 1 % and 3 % polyvinyl alcohol.
- the nonionic surfactant is polyoxyethylene (20) sorbitan.
- the composition comprises between 0.1 % and 1 % of the nonionic surfactant. In one embodiment, the composition comprises between 0.2% and 0.7% of the nonionic surfactant. In another embodiment, the composition comprises 2% polyvinyl alcohol, 2% citric acid and 0.5% of the nonionic surfactant. In one embodiment, the composition further comprises one or more than one type of bactericidal, fungicidal or viricidal agent. In one embodiment, the agent is a multivalent metallic ion. In another embodiment, the agent is a divalent metallic salt. In another embodiment, the agent is selected from the group consisting of copper acetate, copper oxide, copper sulfate and zinc acetate.
- the composition comprises between 0.5% and 5% of each of the one or more than one metallic ion. In another embodiment, the composition comprises between 1 % and 4 % of each of the one or more than one metallic ion. In another embodiment, the composition comprises 3% of each of the one or more than one metallic ion. In one embodiment, the composition comprises 2% citric acid, 2% polyvinyl alcohol, 0.5% polyoxyethylene (20) sorbitan, 3% copper acetate and 3% zinc acetate.
- a polypropylene-based fabric coated with a composition according to the present invention there is provided a polypropylene-based fabric coated with a composition according to the present invention.
- a polypropylene-based material comprising a plurality of layers, where one or more than one of the plurality of layers comprises a polypropylene-based fabric according to the present invention.
- a device that decreases the transmission of one or more than one human pathogen by antibacterial, antifungal and antiviral activity.
- the device comprises a polypropylene-based fabric or a polypropylene-based material according to the present invention.
- a facial mask that decreases the transmission of one or more than one human pathogen by antibacterial, antifungal and antiviral activity.
- the facial mask comprises a polypropylene- based fabric or a polypropylene-based material according to the present invention.
- the facial mask further comprises one or more than one reactive dye.
- a facial mask that decreases the transmission of one or more than one human pathogen by antibacterial, antifungal and antiviral activity.
- the facial mask comprises a polypropylene- based material comprising four layers, Layer #1, Layer #2, Layer #3 and Layer #4 oriented from the front surface to the back surface; where Layer #1 comprises spunbond nonwoven polypropylene fiber having a density of 45 g/m 2 and coated with a composition comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan, Layer #2 comprises spunbond nonwoven polypropylene fiber having a density of 45 g/m 2 and coated with a composition comprising 2% citric acid, 2% polyvinyl alcohol, 0.5% poly oxy ethylene (20) sorbitan, 3% copper acetate and 3% zinc acetate, Layer #3 comprises melt-blown polypropylene fiber having a density of 18 g/m 2 , and Layer #4 comprises spunbond nonwoven polypropylene fiber having
- a facial mask for decreasing the transmission of one or more than one human pathogen to and from a human wearer of the facial mask.
- the facial mask comprises a) a body comprising a front surface of the body, an opposing back surface of the body, and a perimeter of the body defining a shape of the body; and b) a flap attached to the body at a body-flap junction; the flap comprising a front surface of the flap, an opposing back surface of the flap, and a perimeter of the flap defining a shape of the flap; where the body and the flap comprise a polypropylene-based material comprising four layers, Layer #1, Layer #2, Layer #3 and Layer #4 oriented from the front surface to the back surface; and where Layer #1 comprises spunbond nonwoven polypropylene fiber having a density of 45 g/m 2 and coated with a composition comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan, Layer #2 comprises spunbond nonwoven
- a facial mask for decreasing the transmission of one or more than one human pathogen to and from a human wearer of the facial mask.
- the facial mask comprises a) a body comprising a front surface of the body, an opposing back surface of the body, and a perimeter of the body defining a shape of the body, and a central seam; b) a flap attached to the body at a body-flap junction; the flap comprising a front surface of the flap, an opposing back surface of the flap, and a perimeter of the flap defining a shape of the flap; c) a resilient member attached to the back surface of the flap; d) a deformable strip attached to the body; and e) one or more than one extension attached to the body for securing the facial mask to the head of a wearer; where the perimeter of the body comprises a right lateral edge, a left lateral edge connected to the right lateral edge at a bottom junction of the perimeter, and a top edge connecting the right lateral
- Figure 1 is a frontal perspective view of one type of conventional facial mask
- Figure 2 is a back perspective view of the conventional facial mask shown in Figure l
- Figure 3 is a frontal perspective view of one embodiment of a facial mask according to the present invention
- Figure 4 is a frontal-lateral perspective view of the embodiment of the facial mask shown in Figure 3;
- Figure 5 is a back perspective view of the embodiment of the facial mask shown in Figure 3;
- Figure 6 is a partial, cutaway, lateral perspective view of the embodiment of the facial mask shown in Figure 3 taken along the line 6-6;
- Figure 7 is a frontal perspective view of the embodiment of the facial mask shown in Figure 3 through Figure 6 being worn by a wearer;
- Figure 8 is a back perspective view of part of the facial mask shown in Figure 3 before final assembly;
- Figure 9 is a partial, cutaway, frontal perspective view of the facial mask shown in Figure 3 showing the multiple layers of the body of the facial mask;
- Figure 10 is a partial, frontal perspective view of a fabric according to the present invention.
- Figure 11 is a partial, cutaway, frontal perspective view of a material according to the present invention, comprising the fabric shown in Figure 10, and comprising three layers;
- Figure 12 is a partial, cutaway, frontal perspective view of another material according to the present invention, comprising the fabric shown in Figure 10, and comprising four layers;
- Figure 13 is a frontal perspective view of the embodiment of the facial mask shown in Figure 1 and Figure 2 being worn by a wearer.
- a composition for coating a polypropylene-based fabric or polypropylene-based material such as for example a fabric or a material for use in decreasing the transmission of the human pathogens.
- the composition comprises an aqueous solution of citric acid, polyvinyl alcohol and one or more than one nonionic surfactant.
- the composition further comprises one or more than one type of bactericidal, fungicidal or viricidal agent, such as for example an agent selected from the group consisting of copper acetate, copper oxide, copper sulfate and zinc acetate.
- a polypropylene-based fabric coated with a composition according to the present invention there is provided.
- a polypropylene-based material comprising a plurality of layers, where one or more than one of the plurality of layers comprises a polypropylene-based fabric according to the present invention.
- a device that decreases the transmission of one or more than one human pathogen by antibacterial, antifungal and antiviral activity.
- the device comprises a polypropylene-based fabric or a polypropylene-based material according to the present invention.
- a facial mask that decreases the transmission of one or more than one human pathogen by antibacterial, antifungal and antiviral activity.
- the facial mask comprises a polypropylene-based fabric or a polypropylene-based material according to the present invention.
- the facial mask further comprises one or more than one reactive dye.
- a method of decreasing the transmission of one or more than one human pathogen comprises a) providing a facial mask according to the present invention; and b) wearing the facial mask.
- human pathogen comprises bacteria, fungi and viruses, or other microorganisms that cause human diseases, including bacteria, fungi and viruses or other microorganisms that cause human respiratory tract infections.
- overlap means a piece of the facial mask that when folded over at the body-flap junction toward the back surface of the body of the facial mask, inverts the layers of the material of the flap with respect to the layers of material of the body.
- a pleat in a conventional facial mask is not a "flap" within the meaning of the present disclosure, because no such inversion of the layers of the material occur no matter how the pleats are opened or closed during use of the conventional facial mask.
- a material comprises a plurality of layers, such as a layer of fabric according to the present invention.
- resilient member means a substrate that readily regains its original shape after compression, where the resilient member has a first thickness before the application of a compressive force, a second thickness after the application of the compressive force, and a third thickness after the cessation of the application of the compressive force, where second thickness is 75% or less of the first thickness, and where the third thickness is between 90% and 100% of the first thickness, where the thicknesses can be measured at any location across the substrate.
- binding substance means a chemical group that chemically binds a human pathogen, rather than presenting only a physical barrier to spatial passage of the human pathogen.
- binding and its related terms such as “binds,” “binding” and “binding action,” refer to a chemical process, not merely the presentation of only a physical barrier to the spatial passage of the human pathogen.
- cellulosic means “comprising cellulose.”
- an aqueous solution of between 0.5% and 4% polyvinyl alcohol . . . means ' 100 grams of aqueous solution contains between 0.5 grams of polyvinyl alcohol and 4 grams of polyvinyl alcohol . . . '
- the conventional facial mask 10 comprises a body 12 for covering the mouth and nose of a human wearer, and further comprises one or more than one extension 14 joined to the body 12 for securing the facial mask 10 to the head of the wearer.
- the body 12 comprises a material 16 having a front surface 18 and an opposing back surface 20.
- the body 12 further comprises a perimeter 22 comprising a top edge 24, a bottom edge 26, and two lateral edges 28, 30 each connecting the top edge 24 with the bottom edge 26.
- the body 12 further comprises a plurality of pleats 32, each pleat extending from one lateral edge 28 to the other lateral edge 30, the pleats 32 allowing expansion of the body 12 centrally thereby forming a convex shape toward the front surface 18 of the body 12 when expanded, in order to more closely approximate the facial curves of a wearer of the facial mask 10.
- a facial mask for decreasing the transmission of one or more than one human pathogen to and from a human wearer of the facial mask.
- Figure 3 a frontal perspective view of one embodiment of a facial mask according to the present invention
- Figure 4 a frontal-lateral perspective view of the embodiment of the facial mask shown in Figure 3
- Figure 5 a back perspective view of the embodiment of the facial mask shown in Figure 3
- Figure 5 a partial, cutaway, lateral perspective view of the embodiment of the facial mask shown in Figure 3 taken along the line 6-6 ( Figure 6); a frontal perspective view of the embodiment of the facial mask shown in Figure 3 through Figure 6 being worn by a wearer (Figure 7); a back perspective view of part of the facial mask shown in Figure 3 before final assembly (Figure 8); and a partial, cutaway, frontal perspective view of the facial mask shown in Figure 3 showing the multiple layers of the body of the facial mask ( Figure 9).
- the facial mask 100 comprises a body 102 for covering the mouth and nose 302 of a human wearer 300, and further comprises a flap 104 attached to the body 102 at a body-flap junction 106.
- the body 102 comprises a front surface 108 of the body 102, an opposing back surface 110 of the body 102, and a perimeter 112 of the body 102 defining a shape of the body 102.
- the shape of the body 102 can be any suitable shape for the purpose intended, as will be understood by those with skill in the art with reference to this disclosure. In one embodiment, the shape of the body 102 is selected from the group consisting of irregular, oval, rectangular, round, square and triangular.
- the shape of the body 102 defined by the perimeter 112 of the body 102 comprises a right lateral edge 114 (orientation given from the wearer's perspective when wearing the mask), a left lateral edge 116 connected to the right lateral edge 114 at a bottom junction 118 of the perimeter 112, and a top edge 120 connecting the right lateral edge 114 to the left lateral edge 116, where the perimeter 112 of the body 102 when viewed from the front is essentially triangular in shape as shown.
- the top edge 120 partially forms the body-flap junction 106, as can be seen most clearly in Figure 5 and Figure 6.
- the body 102 further comprises a central seam 122.
- the flap 104 of the facial mask 100 comprises a front surface 124 (orientation given before folding the flap 104 into the final configuration of the facial mask 100) of the flap 104, an opposing back surface 126 of the flap 104, and a perimeter 128 of the flap 104 defining a shape of the flap 104.
- the shape of the flap 104 can be any suitable shape for the purpose intended, as will be understood by those with skill in the art with reference to this disclosure. In one embodiment, the shape of the flap 104 is selected from the group consisting of pentagonal, rectangular and triangular.
- the shape of the flap 104 defined by the perimeter 128 of the flap 104 is an inverted U-shape when looking at the front surface 108 of the body 102 or the back surface 108 of the body 102 with the bottom junction 118 oriented down.
- U-shape is the shape of the flap 104 depicted in Figure 3, Figure 5 and Figure 8 (but not inverted in Figure 8).
- this inverted U-shape is particularly advantageous because it permits the flap to more closely approximate the nose 302 of a wearer 300 when the facial mask 100 is worn by the wearer 300 by compensating for the protrusion of the wearer's nose 302 at the base of the wearer's nose 302 than pentagonal, rectangular or triangular shapes.
- the perimeter 128 of the flap 104 comprises in continuity from right to left (orientation given from the wearer's perspective when wearing the mask), a right vertical side 130, a right arcuate side 132, a central curved region 134, a left arcuate side 136, a left vertical side 138, and a base 140 partially forming the body-flap junction 106 and connecting the right vertical side 130 to the left vertical side 138.
- the facial mask 100 further comprises a resilient member 142 attached to the body 102 or the flap 104.
- the resilient member 142 permits the facial mask 100 to more closely approximate the nose 302 of a wearer 300 when the facial mask 100 is worn by the wearer 300 by compensating for the various curves of the wearer's nose 302.
- the resilient member 142 is attached to the back surface 20 of the body 12, or to the front surface 124 of the flap 104.
- the resilient member 142 is attached to the back surface 126 of the flap 104 because this orientation creates a better fit of the facial mask 100 for a greater number of potential wearers while exposing infectious particles that ingress or egress the facial mask 100 past the top edge 24 of the perimeter 22 of the body 12 to the front surface 124 of the flap 104 when the front surface 124 of the flap 104 comprises a fabric for use in decreasing the transmission of human pathogens that binds infectious particles as disclosed below.
- the resilient member 142 can comprise any substance suitable for the intended purpose, as will be understood by those with skill in the art with reference to this disclosure.
- the resilient member 142 is a sponge.
- the resilient member 142 comprises polyurethane.
- the facial mask 100 further comprises a deformable strip 144 attached to the body 102 or the flap 104.
- the deformable strip 144 is particularly advantageous because the deformable strip 144 permits the facial mask 100 to be adjusted by a wearer 300 to more closely approximate the nose 302 of the wearer 300 when the facial mask 100 is worn by the wearer by compensating for the various curves of the wearer's nose 302.
- the deformable strip 144 is attached to the back surface 20 of the body 12, or to the front surface 124 of the flap 104 or to the back surface 126 of the flap 104.
- the deformable strip 144 is attached to the front surface 108 of the body 102 near the top edge 24 overlying the flap, so that deforming the deformable strip 144 imparts deformation to the resilient member 142 and the remainder of the flap 104 also, as will be understood by those with skill in the art with reference to this disclosure.
- the deformable strip 144 comprises a substance which can be easily deformed by the wearer 300.
- the deformable strip 144 can comprise any substance suitable for the intended purpose, as will be understood by those with skill in the art with reference to this disclosure.
- the deformable strip 144 comprises plastic or comprises spring steel wires encased in plastic.
- the deformable strip 144 comprises a malleable aluminum.
- the facial mask 100 further comprises one or more than one extension 146 attached to the body 102 for securing the facial mask 100 to the head of a wearer 300.
- the extension 146 can comprise an elastic substance such as natural rubber, or synthetic rubber or other stretchable polymers, or can comprise a non-elastic substance such as non-elastic cloth or plastic, and can be in the form of ties that encircle the wearer's ears 304 or face 306 or ear loops, with or without adjusters 148 as shown in the Figures.
- the one or more than one extension 146 is a series of adhesive strips to allow attachment of the facial mask 100 to a wearer's face 306.
- the fabric 200 according to the present invention comprises binding substances 202.
- the fabric 200 according to the present invention comprises a composition 202 for coating a polypropylene- based fabric or polypropylene-based material as disclosed in this disclosure.
- the fabric comprises spunbond polypropylene fiber.
- the density of the spunbond polypropylene fiber is between 10 g/m 2 and 50 g/m 2 .
- the density of the spunbond polypropylene fiber is 25 g/m 2 . In another particularly preferred embodiment, the density of the spunbond polypropylene fiber is 45 g/m 2 .
- a device for decreasing the transmission of one or more than one human pathogen where the device comprises a fabric 200 according to the present invention.
- the device is a facial mask according to the present invention, such as a facial mask 100.
- both the body 102 and the flap 104 comprise a fabric 200 according to the present invention.
- a material for decreasing the transmission of one or more than one human pathogen there is provided.
- the material 204 comprises a fabric 200 according to the present invention.
- a device for decreasing the transmission of one or more than one human pathogen where the device comprises a material 204 according to the present invention.
- the device is a facial mask according to the present invention, such as a facial mask 100.
- both the body 102 and the flap 104 comprise a material 204 according to the present invention.
- the material 204 according to the present invention comprises a plurality of layers, where one or more than one layer comprises the fabric 200.
- the material 204 can comprise two layers, three layers, four layers or more than four layers, as will be understood by those with skill in the art with reference to this disclosure.
- the plurality of layers is three layers (as shown in Figure 11, designated here A, B and C).
- the plurality of layers is four layers (as shown in Figure 12, designated here A, B, C and D).
- the body 102 and flap 104 of the facial mask 100 comprises a material 204 according to the present invention and both the front surface 108 of the body 102 and the front surface 124 of the flap 104 comprise a fabric 200 according to the present invention. At least one of the layers of the material 204 comprises a fabric 200 (shown in Figure
- two of the layers of the material 204 comprise a fabric 200.
- one or more than one of the layers of the material 204 is a heat-moldable fabric, such as a heat-moldable fabric selected from the group consisting of polypropylene, polyester and non-woven cellulose acetate fabric.
- the heat-moldable fabric is selected from the group consisting of spunbond nonwoven polypropylene fiber (SBPF) (also called spunbonded nonwoven polypropylene), and melt blown polypropylene fiber (MBPF).
- SBPF spunbond nonwoven polypropylene fiber
- MBPF melt blown polypropylene fiber
- the heat-moldable fabric comprises a spunbond/melt blown fiber composite comprising alternating spunbond (S) and melt blown layers (M), such as for example MS, SM, SMS, SSMS, SMSS, SMSMS, SMMSS and SSMMS.
- S spunbond
- M melt blown layers
- Such heat-moldable layers permit shaping of facial masks with heat or ultrasonic welding according to the present invention.
- heat-moldable layers trap airborne particles, but is hydrophobic so that infectious particle-laden droplets are normally not disrupted even if the infectious particle-laden droplets are trapped within the layer allowing the fabric 200 according to the present invention to bind the infectious particles.
- the hydrophobic layer repels moisture, and hence when the back surface 110 of the body 102 is a hydrophobic layer, the wearer 300 of the facial mask 100 will not feel moisture or wetness against their face 306.
- the material 204 comprises three layers, a first layer of spunbond polypropylene fiber (layer A), a second layer of fabric according to the present invention (layer B), and a third layer of melt-blown polypropylene fiber (layer C).
- the density of the spunbond polypropylene fiber is between 10 g/m 2 and 50 g/m 2 .
- the density of the spunbond polypropylene fiber is 25 g/m 2 .
- the density of the spunbond polypropylene fiber is 45 g/m 2 .
- the density of the melt-blown polypropylene fiber is between 15 g/m 2 and 25 g/m 2 .
- the density of the melt-blown polypropylene fiber is 18 g/m 2 .
- the material 204 comprises three layers, a first layer of spunbond polypropylene fiber (layer A) having a density of 45 g/m 2 , a second layer of fabric according to the present invention (layer B), a third layer of spunbond/melt blown fiber composite (layer C) having a density of 18 g/m 2 .
- the material 204 comprises four layers, a first layer of spunbond polypropylene fiber (layer A), a second layer of fabric according to the present invention (layer B), a third layer of melt-blown polypropylene fiber (layer C), and a fourth layer of spunbond polypropylene fiber (layer D).
- the density of the spunbond polypropylene fiber is between 10 g/m 2 and 50 g/m 2 . In a particularly preferred embodiment, the density of the spunbond polypropylene fiber is 25 g/m 2 . In another particularly preferred embodiment, the density of the spunbond polypropylene fiber is 45 g/m 2 .
- the density of the melt-blown polypropylene fiber is between 15 g/m 2 and 25 g/m 2 . In a particularly preferred embodiment, the density of the melt-blown polypropylene fiber is 18 g/m 2 .
- the material 204 comprises four layers, a first layer of spunbond polypropylene fiber (layer A) having a density of 45 g/m 2 , a second layer of fabric according to the present invention (layer B), a third layer of melt-blown polypropylene fiber (layer C) having a density of 18 g/m 2 , and a fourth layer of spunbond polypropylene fiber (layer D) having a density of 25 g/m 2 .
- the fabric 200 comprises one or more than one binding substance 202 that binds one or more than one type of human pathogen.
- the fabric 200 comprises one or more than one binding substance 202 that binds one or more than one type of virus, such as influenza virus, that causes human respiratory tract infections such as influenza.
- the one or more than one binding substance 202 comprises one or more than one human pathogen binding group for chemically attaching the human pathogen to the binding substance, as will be understood by those with skill in the art with reference to this disclosure.
- the binding substance 202 further comprises a linker group (such as for example a vinyl sulfone group) for attaching the binding substance 202 to the fabric 200.
- the human pathogen to be bound to the fabric 200 is selected from the group consisting of adeno-associated virus (AAV), herpes simplex virus (HSV), human papillomavirus (HPV), influenza viruses, rabies virus, respiratory syncytial virus (RSV), and the human pathogen binding group is a sialic acid group because these virus particles bind to human cells through a terminal sialic acid group on a surface oligosaccharide of the cell membrane of human cells.
- AAV adeno-associated virus
- HSV herpes simplex virus
- HPV human papillomavirus
- influenza viruses rabies virus
- RSV respiratory syncytial virus
- the human pathogen binding group is a sialic acid group because these virus particles bind to human cells through a terminal sialic acid group on a surface oligosaccharide of the cell membrane of human cells.
- the binding substance 202 is a substance that mimics the binding action of sialic acid groups on influenza viruses, but that is cost effective as a component for industrial-scale production of fabrics comprising the binding substance according to the present invention.
- the one or more than one binding substance 202 comprises a human pathogen binding group selected from the group consisting of a sulfate group (such as for example, sulfated monosaccharide or sulfated oligosaccharide) and a sulfonate group (such as for example sulfonated monosaccharide or sulfonated oligosaccharide), because both sulfate groups and sulfonate groups mimic the binding action of sialic acid groups on adeno-associated virus (AAV), herpes simplex virus (HSV), human papillomavirus (HPV), influenza viruses, rabies virus, respiratory syncytial virus (RSV), as well as other human pathogens, while sulfate groups and sulfonate groups can be directly linked to free hydroxyl groups and free amino groups on fibers or fabrics in a cost-effective manner for industrial-scale production in fabrics 200 according to the present invention
- the fabric 200 is a cellulosic fabric (i.e., comprises cellulose) and the one or more than one binding substance 202 comprises a human pathogen binding group comprising a sulfate group, yielding a fabric comprising a non-hydrogel cellulose sulfate.
- the human pathogen binding group is one or more than one reactive dye comprising one or more than one sulfonate group.
- the fabric 200 is a cellulosic fabric (i.e., comprises cellulose) and the binding substance 202 is one or more than one reactive dye comprising a sulfonate group, yielding a fabric 200 comprising a cellulose sulfonate.
- Reactive dyes are a class of substances used to dye fibers and fabrics, both cellulosic fibers and cellulosic fabrics (such as acetate, cotton and rayon), and non-cellulosic fibers and non-cellulosic fabrics (such as wool and nylon, and fabrics made from polyester or poly olefin).
- Reactive dyes comprise a reactive linker group, usually either a haloheterocycle or an activated double bond that, when applied to a fiber in a dye bath, forms a covalent chemical bond with an hydroxyl group on the fiber or the fabric.
- Reactive dyes are classified according to the category of linker group that attaches the dye to the fiber or fabric.
- the binding substance is one or more than one reactive dye selected from the group consisting of aminochlorotriazine (Procion7 H), aminochlorotriazine-sulfatoethylsulfone (Sumafix Supra), aminofluorotriazine (Cibachron F), aminofluorotriazine-sulfatoethylsulfone (Cibacron C), bis(aminochlorotriazine) (Procion7 H-E) bis(aminonicotinotriazine) (Kayacelon React7), chlorodifluoropyrimidine (Drimarine K), dichloroquinoxaline (Levafix7 E), dichlorotriazine (Procion MX), sulfatoethylsulfone (vinyl sulfone; Remazol7), sulfatoethylsulfonamide (Remazol7 D), trichloropyrim
- Reactive Dyes further comprise a chromophore group, providing the specific color for the dye.
- the chromophore group commonly comprises a multi-ring aromatic group; however, multi-ring aromatic groups tend to decrease water solubility, so reactive dyes usually further comprise one or more sulfonate groups to increase water solubility.
- the sulfonate groups of reactive dyes can function as the human pathogen binding group of the binding substance of the fabrics of the present invention, while the reactive linker groups of the reactive dyes can function as the linker group of the binding substance.
- the one or more than one binding substance 202 is a reactive dye selected from the group consisting of CI Reactive Blue 4, CI Reactive Blue 21, CI Reactive Blue 140, CI Reactive Blue 163, CI Reactive Brown 23, CI Reactive Orange 4, CI Reactive Red 1, CI Reactive Red 2, CI Reactive Red 6, CI Reactive Red 11, CI Reactive Red 78, CI Reactive Yellow 39, and CI Reactive Yellow 86, each of which comprises sulfonate groups which function as the human pathogen binding group suitable for binding one or more than one human pathogen according to the present invention, and each of which further comprises a linker group suitable for attaching the binding substance (the dye) to the fabric.
- CI Reactive Blue 4 CI Reactive Blue 21, CI Reactive Blue 140, CI Reactive Blue 163, CI Reactive Brown 23, CI Reactive Orange 4, CI Reactive Red 1, CI Reactive Red 2, CI Reactive Red 6, CI Reactive Red 11, CI Reactive Red 78, CI Reactive Yellow 39, and CI Re
- the binding substance is Reactive Blue 21 [copper, (29H, 3 IH -phthalocyaninato(2-)-N 29 ,N 30 ,N 3l ,N 32 )-, sulfo((4-((2-sulfooxy)ethyl)sulfonyl)phenyl)amino) sulfonyl derivs] (CAS Reg. No. 73049-92-0), a sulfonated copper phthalocyanine dye with a vinyl sulfone linker group that attaches the dye to fibers and fabrics, including cellulosic fibers and fabrics.
- the binding substance 202 cannot render the fabric impermeable to gases when the fabric 200 is to be incorporated into the body of a facial mask 100 according to the present invention because such impermeability would render the facial mask 100 non- functional, as will be understood by those with skill in the art with reference to this disclosure.
- the sulfate group cannot form a cellulose sulfate hydrogel within the fabric because cellulose sulfate hydrogels would block the passage of air through a facial mask rendering the facial mask non- functional and, therefore, the use of the term "cellulose sulfate" and its related terms when referencing the content of a fabric according to the present invention is understood not to comprise a cellulose sulfate hydrogel or any form that is impermeable to gas that would block the passage of air through a facial mask rendering the facial mask non-functional (that is, rendering a wearer unable to breathe adequately through the facial mask).
- a reactive dye as the binding substance 202 in the fabric 200 of the facial mask 100 according to the present invention is particularly advantageous because the amount of reactive dye binding to a fabric is never high enough to cause the sulfonate groups in the reactive dyes to make a hydrogel in the fabric.
- both cellulose sulfate and cellulose sulfonate have surfactant properties, so that fabrics 200 comprising cellulose sulfate or cellulose sulfonate disrupt virus-laden droplets and exposes the virus particles to the sulfate groups on the cellulose sulfate, and to the sulfonate groups on the cellulose sulfonate, thereby trapping the virus particles within the fabric 200.
- the fabric 200 further comprises one or more than one additional substance, other than the binding substance 202 and the fibers of the fabric 200, that decreases the pathogenic capacity of one or more than one human pathogen.
- the one or more than one additional substance is one or more than one type of multivalent metallic ion, such as for example multivalent copper, multivalent silver or multivalent zinc, all of which are antibacterial, antifungal and antiviral.
- the metallic salt is a divalent metallic salt, such as one or more than one divalent metallic salt selected from the group consisting of a salt of divalent copper and a salt of divalent zinc.
- the one or more than one substance is a metallic salt, such as for example a metallic salt selected from the group consisting of copper acetate, copper oxide, copper sulfate and zinc acetate all of which are bactericidal, viricidal and fungicidal.
- a metallic salt selected from the group consisting of copper acetate, copper oxide, copper sulfate and zinc acetate all of which are bactericidal, viricidal and fungicidal.
- a binding substance 202 comprising a sulfate group or a sulfonate group on a fabric 200 comprising cellulose is both relatively inexpensive and suitable for industrial-scale production of facial masks 100 according to the present invention to protect large populations from the transmission of influenza viruses and other human pathogens.
- the fabric 200 is safe to both people and pets, for example by replacing toxic antimicrobial compounds used in some facial masks, and by binding the virus particles within the fabric 200 so that the virus particles do not leach out of the fabric 200 after the virus particles contact the fabric
- the fabric 200 does not require illumination and singlet oxygen generation for decreasing the transmission of one or more than one human pathogen, as with some fabrics designed to decrease transmission of one or more than one human pathogen.
- the fabric 200 is woven, such as for example woven rayon.
- the fabric 200 is non-woven, such as for example non-woven rayon.
- the facial mask 100 comprises a fabric 200 for use in decreasing the transmission of one or more than one human pathogen according to the present invention.
- facial mask 100 comprises a fabric 200 as disclosed in this disclosure and as shown in Figure 10.
- facial mask 100 comprises a material as disclosed in this disclosure and as shown in Figure 11 and Figure 12.
- the method produces a fabric 200 according to the present invention.
- the method will now be disclosed by way of example only primarily with respect to making a fabric comprising cellulose (in this example, rayon) with binding substances comprising sulfate groups as the human pathogen binding group, though other methods can be used to produce the same fabric, and corresponding fabrics with other binding substances (such as sulfonate groups) according to the present invention, as will be understood by those with skill in the art with reference to this disclosure.
- the method comprises, first, providing fibers suitable for use in a fabric 200 for decreasing the transmission of one or more than one human pathogen.
- the fabric comprises cellulose.
- the fabric comprises rayon (a form of cellulose).
- the most important source of cellulose fibers for commercial purposes is from wood pulp; however, cellulose fibers obtained directly from wood pulp are too short and coarse to weave into a fabric according to the present invention, and cellulose derived from wood pulp is relatively insoluble in organic solvents and cannot be extruded into fine fibers.
- rayon fibers are produced from naturally occurring cellulose polymers derived from wood pulp and other plants.
- the cellulose is first derivatized with solubilizing groups (such as for example acetate), formed into spun fibers, and then, the solubilizing groups are removed yielding cellulose fibers that can be woven into fabric, as will be understood by those with skill in the art with reference to this disclosure.
- solubilizing groups such as for example acetate
- the solubilizing groups are removed yielding cellulose fibers that can be woven into fabric, as will be understood by those with skill in the art with reference to this disclosure.
- the method comprises adding one or more than one binding substance to the fibers. Adding the binding substance to the fibers can be accomplished using techniques known to those with skill in the art, as will be understood by those with skill in the art with reference to this disclosure.
- the binding substance added is a binding substance according to the present invention.
- the method will be disclosed with respect to binding substances comprising a human pathogen binding group that comprises a sulfate group, thereby yielding sulfated cellulose fibers.
- adding one or more than one binding substance to the fibers results in sulfation of the cellulose derived fibers in the fabric without disrupting the structure or strength of the fabric.
- sulfate groups to cellulosic fibers (such as rayon)
- equivalent steps can be used for adding sulfate groups to other cellulosic fabrics, blends of cellulose-derived and noncellulose-derived fibers (such as for example fibers made from polyester or polyolefin) and noncellulose-derived fibers that comprise free hydroxyl or amino groups, as will be understood by those with skill in the art with reference to this disclosure.
- Cellulose is a linear polymer of glucose units, each of which has three free hydroxyl groups.
- the degree of sulfation (DS) of cellulose is defined in the art as the average number of sulfate groups per monosaccharide unit.
- a DS of 3 is the maximum possible, indicating that all available hydroxyl groups are fully sulfated.
- a degree of sulfation of 1 indicates that an average of one sulfate group per glucose unit is present, and a DS of 0.1 , for example, indicates that an average of one hydroxyl group of every ten glucose units is sulfated.
- An important aspect of the present invention is that the binding of viruses and other human pathogens to a fiber or fabric according to the present invention involves binding of the human pathogen to more than one immobilized sulfate group or sulfonate group on the fiber or fabric, thereby strongly increasing the affinity of the interaction between the binding substance and the human pathogen.
- the degree of sulfation is determined by any suitable analytical method that measures sulfate, sulfonate or total sulfur, such as for example by elemental analysis.
- the sulfur content of cellulose fibers without a binding substance attached or nonpigmented cellulose fibers or fabrics is extremely low or undetectable.
- the present method results in a degree of sulfation between 0.02 and 2.
- the present method results in a degree of sulfation between 0.05 and 0.5.
- the present method results in a degree of sulfation of between 0.09 and 0.21.
- the degree of sulfation for sulfated or sulfonated fibers or fabric can be regulated by adjusting the time, temperature or reagent concentrations in a sulfation or sulfonation reaction, as will be understood by those with skill in the art with reference to this disclosure, to produce fibers with the required degree of sulfation.
- the method further comprises crosslinking the fibers of the fabric, before or after attaching the binding substance, by treating the fabric with one or more than one crosslinking agent that chemically bonds the fibers of the fabric to one another thereby preventing solubilization.
- treating the fabric with a crosslinking agent comprises contacting the fabric with an alkali, e.g. , sodium hydroxide, to give the alkalinized cellulose in the case of cellulosic fabrics, and then reacting the fabric with the crosslinking agent.
- the crosslinking agent is selected from the group consisting of dichloroalkanes, dimethylolureas, formaldehyde and trimethylol-melamines.
- the crosslinking agent is an epoxy compound selected from the group consisting of diethylene glycol diglycidyl ether, ethylene glycol diglycidyl ether, epichlorohydrin, glycerin diglycidyl ether and vinylcyclohexene dioxide.
- Adding one or more than one binding substance comprising a sulfate human pathogen binding group to the fibers can be accomplished, for example, by first, contacting the fabric with a suitable solvent, such as for example dimethylsulfoxide (DMSO) or dimethylformamide (DMF).
- a suitable solvent such as for example dimethylsulfoxide (DMSO) or dimethylformamide (DMF).
- DMSO dimethylsulfoxide
- DMF dimethylformamide
- the solvent treated fabric is contacted with the binding substance, such as for example a sulfating reagent.
- a sulfating reagent Suitable sulfating reagents depend on the solvent used, as will be understood by those with skill in the art with reference to this disclosure.
- the solvent is dimethylsulfoxide, and the sulfating reagent is DMSO treated with sulfur trioxide (DMSO-SO 3 ).
- the solvent is dimethylformamide, and the sulfating reagent is dimethylformamide treated with sulfur trioxide (DMF-SO 3 ).
- the method further comprises rinsing the fabric with a solvent, such as for example (DMSO-SO 3 ) and (DMF-SO 3 ) and then contacting the fabric with a suitable base, such as for example sodium hydroxide, sodium acetate, or sodium bicarbonate, to neutralize an acidic binding substance such as an acidic sulfating agent, or to neutralize acid formed during the addition of the binding substance to the fabric.
- a suitable solvent such as for example water or a simple alcohol (ethanol or isopropanol) to remove unreacted reagents yielding the sulfated fabric suitable for use in decreasing the transmission of one or more than one human pathogen, including viruses that cause human respiratory tract infections.
- the method for making a fabric for use in constructing a facial mask according to the present invention for decreasing the transmission of one or more than one human pathogen comprises, first, providing cellulose sulfate material made from cellulose pulp or cellulose powder and having a degree of sulfation greater than 0.2, and preferably greater than 0.5 sufficient to render the fibers water soluble. Next, the soluble cellulose sulfate is then applied to a fabric and covalently linked to the fibers of the fabric with a crosslinking agent, as disclosed above, as will be understood by those with skill in the art with reference to this disclosure.
- the fabric is not exposed to the relatively harsh sulfation conditions and reagents, but only to soluble cellulose sulfate and to the crosslinking reagents, and to the conditions for crosslinking, thereby reducing the potential for damage to the fabric that can occur if the sulfation reaction is not well controlled.
- a concentration of soluble cellulose sulfate is selected by testing, such that a fabric with acceptable pressure drop characteristics suitable for gas exchange through a facial mask is obtained, especially when the fabric is to be used in a mask according to the present invention, as will be understood by those with skill in the art with reference to this disclosure.
- the method further comprises contacting the fabric with one or more than one substance that chemically disrupts a characteristic of the human pathogen essential for human pathogenicity.
- the one or more than one substance is a multivalent metallic ion, such as for example multivalent copper, multivalent silver or multivalent zinc, all of which are antibacterial, antifungal and antiviral.
- the one or more than one substance is a metallic salt, such as for example copper oxide, zinc acetate, copper acetate or copper sulfate, all of which are bactericidal, viricidal and fungicidal.
- the metallic salt is a divalent metallic salt.
- Acetate is advantageous as an anionic salt constituent as it is volatile and can be removed from the fabric by evaporation, but other anions are also suitable as salt components, including chlorides, oxides, iodides and others.
- the addition of the one or more than one substance to the fabric increases the effectiveness of the facial mask of the present invention in decreasing the transmission of one or more than one human pathogen by using mechanisms in addition to binding the human pathogen to the fabric.
- the method further comprises incorporating one or more than one type of fiber other than the fibers comprising the binding substance, such as for example polyester fibers or polypropylene fibers, into the fabric.
- cellulosic fibers in the form of staple or tow are sulfated by the same types of sulfation reactions used for fabrics as disclosed in this disclosure, and then the cellulose sulfate fibers are washed and then formed into a nonwoven or woven fabric by conventional methods whereby cellulosic staple or tow are spun into threads or directly formed into nonwoven fabrics.
- sulfated rayon was prepared according to the present invention as follows. First, 60 ml isopropanol was chilled on ice and 0.2 grams MgSO 4 was added to the isopropanol to remove water. Next, 240 ml sulfuric acid, previously chilled on ice, was added to the isopropanol. Then, nonwoven rayon fabric having a density of 70 grams/meter 2 was cut into 17.5 cm by 22.5 cm rectangles and laid on polypropylene mesh of approximately the same size. Next, the rayon fabric on the mesh was submerged in chilled acetic acid for 15 minutes.
- the isopropanol/sulfuric acid mixture was poured into a polyethylene box (approximately 30 cm by 37.5 cm) sitting on ice.
- the rayon fabric on the polyethylene mesh was submerged in the isopropanol/sulfuric acid mixture for either 5 minutes or for 10 minutes, and rinsed first in cold isopropanol, and then in cold isopropanol containing 3 grams of sodium acetate per 100 ml, and then in cold isopropanol producing the sulfated rayon fabric.
- the rayon fabric was then allowed to dry while still on the polyethylene mesh. Samples of the sulfated rayon fabric were analyzed for sulfur and carbon content.
- sulfonated rayon fabric was prepared according to the present invention as follows. First, a solution was prepared by adding 30 grams of sodium sulfate to 600 grams distilled water, followed by adding of 4 grams of CI Reactive Blue 21 dye (a sulfonated binding substance). Next, 30 grams of nonwoven rayon fabric having a density of 70 grams/meter 2 were added to the solution and gently swirled until uniformly submerged and wetted. Then, 12 grams of sodium carbonate were added with stirring, and the mixture was held at 30EC for 35 minutes. Next, the temperature was raised to 70EC for an additional 60 minutes yielding the sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance). Then, the sulfonated rayon fabric was rinsed under running water until no more free dye was eluted, and the sulfonated rayon fabric was air-dried.
- CI Reactive Blue 21 dye a sulfonated binding substance
- sulfated cellulose fabric made according to Example 1 or sulfonated cellulose fabric made according to Example 2 was prepared to comprise one or more than one than one additional substance, other than the binding substance, that destroys the pathogenic capacity of one or more than one human pathogen as follows.
- sulfated rayon fabric was made according to the process disclosed in Example 1, or sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) was made according to the process disclosed in Example 2.
- sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) and comprising divalent metal salts was prepared according to the present invention as follows. First, 100% spunlace viscose rayon fabric having a density of 70 grams/meter 2 was dyed with CI Reactive Blue 21 (Novacron7 Turquoise H-GN) at a liquid to solid ratio of 20: 1. Next, 50 g/L sodium sulfate, 20 g/L sodium carbonate and 12% dye by volume (120 ml/L) was added to a dye bath and mixed thoroughly with continuous agitation.
- the rayon fabric was immersed in the dye bath for 35 minutes at a temperature of 30EC, followed by 60 minutes at a temperature of 70EC producing the sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance).
- the sulfonated rayon fabric was rinsed under running water and air-dried.
- 50 grams each of copper acetate and zinc acetate per liter of water was sprayed on the sulfonated rayon at rate 0.08 L/m 2 producing the sulfonated rayon fabric comprising both divalent copper and divalent zinc ions.
- the sulfonated rayon fabric comprising both divalent copper and divalent zinc ions was again air-dried.
- Example 5 Assessment of Fabric for Anti-human Pathogen Properties Testing antiviral properties (as a surrogate for anti-human pathogen properties) of a fabric is performed by application of standardized amounts of a virus onto a piece of test fabric.
- the test fabric is then stirred in cell culture medium to elute any functional virus particles, that is, virus particles that are not inactivated by adherence to the fabric or otherwise to the test fabric.
- Functional virus particles eluted into the culture medium are assayed for viral activity by contacting the medium with cells susceptible to viral killing, and ascertaining a quantitative readout of cell death. Decreased cell death in the eluting medium indicates increased inactivation of the virus by the test fabric through viral adherence to the fabric or otherwise by the test fabric.
- sulfated rayon fabric having a degree of sulfation (DS) of 0.2 made according to Example 1
- sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) made according to Example 2
- sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) comprising both copper sulfate and zinc acetate, made according to Example 3, were assessed for antiviral properties.
- test samples of the sulfated rayon fabric, the sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance), and the sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) comprising both copper sulfate and zinc acetate were submitted to Microbiotest, Inc. (Sterling, VA US) for assessment of the fabric's ability to inactivate the human pathogen herpes simplex virus (HSV).
- HSV human pathogen herpes simplex virus
- HSV was applied in an aerosol to a 5 cm by 5 cm area of the test fabrics, as well as to a non-sulfated, non- sulfonated piece of rayon control fabric, and to a piece of rayon fabric treated only with copper sulfate and zinc acetate (1 gram each per 100 ml water, applied at 40 microliters per square centimeter).
- the HSV-treated fabric samples were held for 1 minute and then placed in individual 20 ml aliquots of extraction medium and subjected to gentle agitation for 5 minutes. Aliquots of the extraction sample were serially diluted 10-fold in dilution medium and inoculated onto host cells. Residual infectious virus in extraction medium from each sample was detected and quantified by their viral-induced cytopathic effects.
- the sulfated rayon fabric prepared according to Example 1 had a 1.87 log reduction in pathogenic virus as compared to the non-sulfated, non-sulfonated rayon control fabric.
- Incorporating copper sulfate and zinc acetate to the non-sulfated, non- sulfonated rayon control fabric yielded a 2.0 log reduction in pathogenic virus as compared to the non-sulfated, non-sulfonated rayon control fabric, where the reduction in pathogenic virus was attributable to the presence of the divalent salts alone.
- Sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) prepared according to Example 2 had a 0.37 log reduction in pathogenic virus as compared to the non-sulfated rayon control fabric.
- the lower limit of detection in the assay system was 3.13 logs, so that the minimum reduction in HSV titer for sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) and treated with copper sulfate and zinc acetate was 4.47 logs.
- a minimum of 2.47 logs further viral inactivation or trapping was achieved with sulfonation and divalent metal ions versus non-sulfated, non-sulfonated rayon fabric incorporating the same amount of divalent metal ions.
- sulfonated rayon fabric with CI Reactive Blue 21 dye as the binding substance
- rayon fabric comprising the divalent metal salts copper sulfate and zinc acetate were assessed for their antiviral properties.
- the results of the testing were that the sulfated rayon fabric made according to Example 1 having a degree of sulfation (DS) of either 0.1 or 0.2, both yielded no detectible pathogenic virus at each of the time points tested (1, 5 and 15 minutes), indicating an influenza virus log reduction greater than 3 at each of the time points tested compared to the amount of virus applied to the fabric.
- DS degree of sulfation
- sulfated rayon fabric made according to Example 1 having a degree of sulfation (DS) of 0.2 and comprising the divalent metal salts copper sulfate and zinc acetate also yielded no detectible pathogenic virus at each of the time points tested (1, 5 and 15 minutes), indicating an influenza virus log reduction greater than 3 at each of the time points tested compared to the amount of virus applied to the fabric.
- DS degree of sulfation
- Sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance), made according to Example 2, reduced influenza A virus in log reductions of 1.95 at a 1 minute test time, 2.33 at a 5 minute test time, and 3.08 at 15 minute test time.
- Sulfonated rayon fabric (with CI Reactive Blue 21 dye as the binding substance) and comprising the divalent metal salts copper sulfate and zinc acetate made according to Example 3, yielded no detectible pathogenic virus at each of the time points tested (1, 5 and 15 minutes), indicating an influenza virus log reduction greater than 3 at each of the time points tested.
- the facial mask 100 comprises a fabric 200 according to the present invention, where the fabric 200 comprises a binding substance 202 according to the present invention.
- the fabric 200 further comprises one or more than one additional substance according to the present invention, other than the binding substance, that decreases the pathogenic capacity of one or more than one human pathogen.
- the one or more than one additional substance is a multivalent metallic ion, such as for example a multivalent metallic ion selected from the group consisting of multivalent copper, multivalent silver and multivalent zinc.
- the one or more than one substance is a metallic salt, such as for example a metallic salt selected from the group consisting of copper acetate, copper oxide, copper sulfate and zinc acetate.
- the metallic salt is a divalent salt.
- the facial mask 100 comprises a fabric 200 comprising CI Reactive Blue 21 dye as the binding substance 202, and the fabric 200 further comprises multivalent copper and multivalent zinc.
- facial mask 100 comprises a body 102, a flap 104, and one or more than one extension 146 attached to the body 102 for securing the facial mask 100 to the face 306 of a wearer.
- the method comprises enclosing or surrounding a fabric 200 as disclosed in this disclosure with one or more than one heat-moldable fabric as disclosed in this disclosure. Such heat-moldable fabrics permit shaping of masks with heat or ultrasonic welding of the facial mask 100.
- the method comprises, first, providing a fabric 200 as disclosed in this disclosure.
- the fabric 200 further comprises one or more than one additional substance according to the present invention, other than the binding substance 202, that decreases the pathogenic capacity of one or more than one human pathogen.
- the one or more than one additional substance is a multivalent metallic ion, such as for example multivalent copper, multivalent silver or multivalent zinc, such as divalent copper or divalent zinc.
- the one or more than one substance is a metallic salt, such as for example copper oxide, zinc acetate, copper acetate or copper sulfate.
- the metallic salt is a divalent metallic salt, such as one or more than one divalent metallic salt selected from the group consisting of a salt of divalent copper and a salt of divalent zinc.
- the fabric 200 is cut and formed to the shape of the facial mask 100, and the one or more than one extension 146 is attached to the body 102 of the facial mask 100.
- the body 102 and flap 104 of the facial mask 100 comprise a material comprising a plurality of layers, such as the material 204 disclosed in this disclosure.
- the plurality of layers is three layers, such as the material 204 shown in Figure 11.
- the plurality of layers is four layers, such as the material 204 shown in Figure 12.
- the method comprises providing a fabric 200 according to the present invention to form one or more than one layer of the material 204.
- the fabric 200 or the material 204 or both the fabric 200 and the material 204 are provided on rolls of a first size, and the rolls are cut to a second size for making the facial mask 100.
- the method comprises cutting the fabric 200, or cutting the layers of the material 204, into the shape of the body 102 and the flap 104.
- the facial mask 100 comprises a material 204 comprising a plurality of layers, and the method comprises assembling the layers of material 204 in the order of the layers, and joining the layers together.
- the layers of the material 204 are joined together by an adhesive to create the perimeter 112 of the body 102 and the perimeter 128 of the flap 104.
- the layers of the material 204 are joined together by ultrasonic welding to create the perimeter 112 of the body 102 and the perimeter 128 of the flap 104.
- the method further comprises labeling the facial mask 100 with text or graphics or both text and graphics identifying the origin or content of the facial mask 100, or providing instructions on wearing the facial mask 100.
- the body 102 and the flap 104 comprise the shape as shown, and the method further comprises creating a central seam 122 of the body 102 by any suitable method as will be understood by those with skill in the art with reference to this disclosure.
- the central seam 122 of the body 102 is created by application of an adhesive.
- the central seam 122 of the body 102 is created by ultrasonic welding.
- the method further comprises attaching one or more than one extension 146 to the body 102.
- the one or more than one extension 146 is attached to the body 102 by application of an adhesive.
- the one or more than one extension 146 is attached to the body 102 by ultrasonic welding.
- the method further comprises attaching the resilient member 142 to the facial mask 100.
- attaching the resilient member 142 to the facial mask 100 comprises applying an adhesive to the resilient member 142 or to the flap 104 or to both the resilient member 142 and to the flap 104, and joining the resilient member 142 to the flap 104 by applying pressure to the resilient member 142 and to the flap 104.
- the method further comprises attaching a deformable strip 144 to the facial mask 100.
- attaching the deformable strip 144 to the facial mask 100 comprises applying an adhesive to the deformable strip 144 or to the body 102 or to both the deformable strip 144 and to the body 102, and joining the deformable strip 144 to the body 102 by applying pressure to the deformable strip 144 and to the body 102.
- the method further comprises folding the flap 104 at the body-flap junction 106 of the facial mask 100 so that the back surface 126 of the flap 104 faces the back surface 110 of the body 102.
- the facial mask 100 is now ready to be worn.
- the method comprises providing a facial mask 100 according to the present invention, and wearing the facial mask 100.
- a first advantage to the facial mask 100 according to the present invention is that the flap 104 of the facial mask 100 according to the present invention confers a better fit than the conventional facial mask 10 around the nose 302 of the wearer 300, and thereby wearing the facial mask 100 according to the present invention, when compared with wearing a conventional facial mask 10, decreases egress of airborne infectious particles outward from the space between the facial mask 100 and the face 306 of the wearer 300 (shown as the up arrow), or decreases ingress of airborne infectious particles from around the perimeter 112 of the facial mask 100 into the space between the facial mask 100 and the face 306 of the wearer 300 (shown as the down arrow), or both decreases egress of airborne infectious particles outward from the space between the facial mask 100 and the face 306 of the wearer 300
- This advantage decreases the transmission of one or more than one human pathogen by preventing contagion of the wearer 300 of the facial mask 100 according to the present invention with infectious particles from a third person, and by decreasing the transmission of one or more than one human pathogen from the wearer 300 of the facial mask 100 according to the present invention to a third party.
- a second advantage to the facial mask 100 is folding the flap 104 over at the body-flap junction 106 toward the back surface 110 of the body 102 of the facial mask 100, inverts the layers of the material 204 of the flap 104 with respect to the layers of material 204 of the body 102.
- This inversion of orientation causes airborne infectious particles expelled from the wearer 300 or entering the space between the facial mask 100 and the face 306 of the wearer 300 from outside the perimeter 112 of the facial mask 100 to encounter the fabric 200, thereby binding some of the infectious particles to the fabric 200, and thereby decreasing the transmission of one or more than one human pathogen by preventing contagion of the wearer 300 of the facial mask 100 according to the present invention with infectious particles from a third person, and by decreasing the transmission of one or more than one human pathogen from the wearer 300 of the facial mask 100 according to the present invention to a third party.
- a composition for coating a polypropylene-based fabric or polypropylene-based material such as for example a fabric or a material according to the present invention for use in decreasing the transmission of the human pathogens.
- the composition decreases the hydrophobicity of the polypropylene-based fabric or polypropylene-based material, thereby increasing the transmission of the human pathogens through the polypropylene-based fabric or polypropylene-based material.
- the composition has additional direct antibacterial, antifungal and antiviral activity.
- the composition provides a durable coating that adheres to the polypropylene-based fabric or polypropylene-based material.
- the composition is compatible with high-speed manufacturing processes such as the ultrasonic shaping and welding of protective face masks that comprise thermoplastic polypropylene- based fabric or polypropylene-based material.
- the composition is coated onto the surface of the polypropylene-based fabric or polypropylene-based material.
- the composition is coated onto two of the two or more than two layers of the polypropylene-based material.
- the composition comprises citric acid (also known as
- polyvinyl alcohol also known as Alkotex; Alvyl; Covol; Ethenol, Gelvatol; homopolymer; Lemol; Mowiol; Poly(Ethenol), Poly viol; PVA; PVOH and Vinol.
- the polyvinyl alcohol is a partially hydrolyzed form of polyvinyl alcohol which allows the composition to optimally adhere to a polypropylene- based fabric or polypropylene-based material while also forming a durable coating when mixed with citric acid (with or without a nonionic surfactant).
- the polyvinyl alcohol is Elvanol ® 51-05 (E. I. du Pont Distal end 28 Nemours and Company Corporation, Delaware, MD US).
- the composition for coating a polypropylene-based fabric or polypropylene-based material further comprises one or more than one nonionic surfactant.
- the nonionic surfactant increases the antibacterial, antifungal and antiviral activity of a polypropylene-based fabric or polypropylene-based material coated with the composition both by direct actions on the pathogenic particles and by increasing the dispersion of the citric acid through the polypropylene-based fabric or polypropylene-based material upon contact of the composition treated polypropylene-based fabric or polypropylene-based material with aerosol droplets containing human pathogens.
- the nonionic surfactant is poly oxy ethylene (20) sorbitan (also known as monolaurate; polysorbate 20; PEG(20) sorbitan monolaurate; and T ween 20).
- the composition is an aqueous solution.
- the water portion of the aqueous solution is distilled water.
- the composition comprises an aqueous solution of between 0.5% to 4% citric acid and between 0.5% and 4% polyvinyl alcohol. In another embodiment, the composition comprises an aqueous solution of between 1 % and 3 % citric acid and between 1 % and 3% polyvinyl alcohol. In a preferred embodiment, the composition comprises an aqueous solution of 2% polyvinyl alcohol and 2% citric acid. In one embodiment, the composition comprises between 0.1 % and 1 % of the nonionic surfactant. In another embodiment, the composition comprises between 0.2% and 0.7% of the nonionic surfactant. In a preferred embodiment, the composition comprises 0.5% of the nonionic surfactant. In a particularly preferred embodiment, the composition is an aqueous solution comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% of the nonionic surfactant.
- the composition for coating a polypropylene-based fabric or polypropylene-based material further comprises one or more than one type of bactericidal, fungicidal or viricidal agent.
- the bactericidal, fungicidal or viricidal agent can be any antibacterial, antifungal and antiviral agent that is physically compatible with the other components of the composition (citric acid, polyvinyl alcohol, and the nonionic surfactant).
- the agent is a multivalent metallic ion, such as for example multivalent copper, multivalent silver or multivalent zinc, all of which are antibacterial, antifungal and antiviral.
- the metallic ion is a divalent metallic salt, such as one or more than one divalent metallic salt selected from the group consisting of a salt of divalent copper and a salt of divalent zinc, such as for example divalent metallic salt selected from the group consisting of copper acetate, copper oxide, copper sulfate and zinc acetate, all of which are bactericidal, viricidal and fungicidal.
- the composition comprises copper acetate and zinc acetate.
- the composition comprises between 0.5% and 5% of each of the one or more than one metallic ion.
- the composition comprises between 1 % and 4% of each of the one or more than one metallic ion.
- the composition comprises 3% of each of the one or more than one metallic ion.
- the composition comprises 3 % copper acetate and 3% zinc acetate.
- the composition increases the hydrophilicity of polypropylene-based fabric (such as for example through spunbond non-woven polypropylene fiber (SBPF) or melt blown polypropylene fiber (MBPF)) or polypropylene-based material when the composition is dried onto the polypropylene-based fabric or polypropylene-based material.
- SBPF spunbond non-woven polypropylene fiber
- MBPF melt blown polypropylene fiber
- the acidic nature of the citric acid component of the composition acts as a hydrophilic plasticizing agent for the polyvinyl alcohol, and also provides an acidic environment that contributes to the total antibacterial, antifungal and antiviral activity of the fabric.
- composition advantageously does not obstruct airflow, making the composition suitable for use on polypropylene-based fabrics and polypropylene-based materials used as part of a protective face mask.
- the composition of the present invention can be made by any suitable process, as will be understood by those with skill in the art with reference to this disclosure.
- the composition is an aqueous solution comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan, and the composition is made by dissolving the citric acid, polyvinyl alcohol and poly oxy ethylene (20) sorbitan in distilled water, boiling the solution at 80 0 C until the polyvinyl alcohol is completely dissolved, and then allowing the solution to cool down to room temperature before use.
- the composition is an aqueous solution comprising 2% citric acid, 2% polyvinyl alcohol, 0.5% poly oxy ethylene (20) sorbitan, 3% copper acetate and 3% zinc acetate, and the composition is made by dissolving sufficient copper acetate powder and zinc acetate powder into the solution made according to the preceding example.
- the composition is applied to a polypropylene-based fabric or polypropylene-based material by any suitable method as will be understood by those with skill in the art with reference to this disclosure, such as for example by dipping the polypropylene-based fabric or polypropylene-based material into the composition, or by spraying or rolling the composition onto the polypropylene-based fabric or polypropylene-based material, and then drying the polypropylene-based fabric or polypropylene-based material.
- drying comprises allowing the composition coated polypropylene-based fabric or composition coated polypropylene-based material to air dry at room temperature.
- drying comprises using forced air or heat, such as for example by contacting the composition coated polypropylene-based fabric or composition coated polypropylene-based material with a heated roller in a production line.
- coating a polypropylene-based fabric or polypropylene-based material with the composition can be accomplished using a continuous production process where rolls of polypropylene- based fabric or polypropylene-based material are coated with the composition and dried, and then the coated polypropylene-based fabric or polypropylene-based material can be fed directly into fabrication machinery for producing a final structure, such as for example a protective face mask, or can be stored for later use.
- the composition can be used on any polypropylene-based fabric or polypropylene-based material, such as for example a polypropylene-based fabric or polypropylene-based material incorporated into a protective face mask.
- a composition coated polypropylene-based material having alternating spunbond non-woven polypropylene fiber (S) and melt blown polypropylene fiber (M) layers, such as for example MS, SM, SMS, SSMS, SMSS, SMSMS, SMMSS and SSMMS.
- the polypropylene-based material having alternating spunbond non- woven polypropylene fiber (S) and melt blown polypropylene fiber (M) layers further comprises one or more than one layer that decreases the transmission of the human pathogen by antibacterial, antifungal and antiviral activity, such as for example, a layer of fabric according to the present invention that decreases the transmission of the human pathogen by antibacterial, antifungal and antiviral activity.
- the polypropylene-based material having the alternating layers is incorporated into a protective face mask.
- compositions according to the present invention for coating a polypropylene-based fabric or polypropylene-based material were tested using four types of material, where each type of material had four layers in the following order: Layer #1: spunbond non- woven polypropylene fiber (SBPF); Layer #2: rayon;
- Layer #3 melt blown polypropylene fiber (MBPF); and Layer #4: spunbond non- woven polypropylene fiber (SBPF).
- MBPF melt blown polypropylene fiber
- SBPF spunbond non- woven polypropylene fiber
- Material #4 Layer #1 dipped in an aqueous composition comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan according to the present invention, then drained and air-dried; Layer #2 comprising Reactive Blue 21 dye, copper acetate and zinc acetate according to the present invention.
- Each of the four materials were tested for antiviral activity by misting 9.6 logs of live Influenza A (HlNl) virus onto 5 cm by 5 cm squares of the material in a volume of 0.4 ml of buffered saline. After exposure times of 1 minute or 5 minutes, each material was transferred to a cell culture medium for extraction of residual live virus, which was then quantified by infectivity in a test cell line according to techniques known to those with skill in the art.
- Material #1 did not reduce viral load at either the contact times of 1 and 5 minutes.
- Material #2 comprising a material according to the present invention reduced viral load by 2 and 2.5 logs at 1 minute and 5 minutes, respectively.
- Material #3 which was identical to Material #2 except that layer #1 was coated with a composition according to the present invention comprising 2 % citric acid and 2% polyvinyl alcohol, reduced viral load by 4.25 logs at both 1 minute and 5 minutes, respectively.
- Material #4 which was identical to Material #2 except that layer #1 was coated with a composition according to the present invention comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan reduced viral load by 5.5 and 6 logs at 1 minute and 5 minutes, respectively.
- coating a polypropylene-based fabric or polypropylene-based material with a composition according to the present invention results in a substantial increase in antiviral activity of the material.
- the effect of increasing the hydrophilicity of the polypropylene-based fabric by coating the polypropylene-based fabric with a composition according to the present invention was demonstrated by comparing the rate of absorption of aqueous droplets applied to Layer #1 (a spunbond polypropylene layer) of samples of Material #2 and Material #4.
- Material #2 and Material #4 were identical except that Material #4 had a coating of the composition comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% polyoxyethylene (20) sorbitan to Layer #1.
- a droplet of distilled water (1 microliter) was dropped onto the surface of Layer #1 of Material #2 and Layer #1 of Material #4.
- the antiviral effectiveness of another composition according to the present invention for coating a polypropylene-based fabric or polypropylene-based material was tested using the following three types of fabrics and two, four-layered type of material as follows: Fabric #1: (the control) nonwoven polypropylene fabric (45 g/m 2 ) with no composition coating; Fabric #2: nonwoven polypropylene fabric (45 g/m 2 ) coated with a composition according to the present invention comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan; Fabric #3: nonwoven polypropylene fabric (45 g/m 2 ) coated with a composition according to the present invention comprising 2% citric acid, 2% polyvinyl alcohol, 0.5% poly oxy ethylene (20) sorbitan, 2% copper acetate and 2% zinc acetate;
- Material #4 four-layered material comprising Layer #1: spunbond non- woven polypropylene fiber (SBPF); Layer #2: nonwoven polypropylene fabric (45 g/m 2 ) coated with a composition according to the present invention comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% poly oxy ethylene (20) sorbitan; Layer #3: melt blown polypropylene fiber (MBPF); and Layer #4: spunbond non- woven polypropylene fiber (SBPF); and Material #5: four-layered material comprising Layer #1: spunbond non- woven polypropylene fiber (SBPF); Layer #2: rayon treated with a composition of Reactive Blue 21 dye, copper acetate and zinc acetate according to the present invention; Layer #3: melt blown polypropylene fiber (MBPF); and Layer #4: spunbond non- woven polypropylene fiber (SBPF).
- SBPF spunbond non- woven polypropylene fiber
- SBPF spunbond non- woven polypropylene fiber
- Each of the three fabrics and two materials were tested for antiviral activity by misting 6.35 logs of live Influenza B (B/Lee/40) virus onto 5 cm by 5 cm squares of the fabrics and material in a volume of 0.4 ml of buffered saline. After an exposure time of 5 minutes, each fabric and material was transferred to cell culture medium for extraction of residual live virus, which was then quantified by infectivity in a test cell line according to techniques known to those with skill in the art.
- a polypropylene-based fabric or polypropylene based material comprising a composition on either one surface or two surfaces.
- a device that decreases the transmission of one or more than one human pathogen by antibacterial, antifungal and antiviral activity where the device comprises a polypropylene-based fabric or polypropylene-based material coated with a composition according to the present invention.
- a method of decreasing the transmission of one or more than one human pathogen where the method comprises providing a device comprising a polypropylene-based fabric or polypropylene-based material coated with a composition according to the present invention, and using the device.
- the device is a facial mask according to the present invention.
- the device is a facial mask according to the present invention, where the body (and the flap when present) of the facial mask comprises four layers oriented from front to back, where Layer #1 comprises spunbond nonwoven polypropylene fiber having a density of 45 g/m 2 and coated with a composition according to the present invention comprising 2% citric acid, 2% polyvinyl alcohol and 0.5% polyoxyethylene (20) sorbitan, Layer #2 comprises spunbond nonwoven polypropylene fiber having a density of 45 g/m 2 and coated with a composition according to the present invention comprising 2% citric acid, 2% polyvinyl alcohol, 0.5% polyoxyethylene (20) sorbitan, 3% copper acetate and 3% zinc acetate, Layer #3 comprises melt-blown polypropylene fiber having a density of 18 g/m 2 , and Layer #4 comprises spunbond nonwoven polypropylene fiber having a density of 25 g/m 2 .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Textile Engineering (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Pulmonology (AREA)
- Business, Economics & Management (AREA)
- Emergency Management (AREA)
- Virology (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080023681.3A CN102448550B (en) | 2009-05-29 | 2010-05-21 | For reducing the compositions of the propagation of human pathogen |
MYPI2011005730A MY188369A (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
KR1020117031441A KR101673044B1 (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
CA2761963A CA2761963C (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
AU2010254319A AU2010254319B2 (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
SG2011087541A SG176254A1 (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
US13/319,836 US9963611B2 (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
EP10781047.5A EP2435139B1 (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
BRPI1011482A BRPI1011482A2 (en) | 2009-05-29 | 2010-05-21 | composition for use in reducing the transmission of human pathogens |
JP2012513146A JP5740653B2 (en) | 2009-05-29 | 2010-05-21 | Composition for use in reducing human pathogen infection |
MX2011012545A MX347440B (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens. |
IL216582A IL216582A (en) | 2009-05-29 | 2011-11-24 | Composition for coating a polypropylene-based material for use in decreasing the transmission of human pathogens, devices comprising the same and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US2009/045621 | 2009-05-29 | ||
PCT/US2009/045621 WO2009146412A1 (en) | 2008-05-30 | 2009-05-29 | Protective face mask |
US29819410P | 2010-01-25 | 2010-01-25 | |
US61/298,194 | 2010-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010138426A1 true WO2010138426A1 (en) | 2010-12-02 |
Family
ID=43223025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/035864 WO2010138426A1 (en) | 2009-05-29 | 2010-05-21 | Composition for use in decreasing the transmission of human pathogens |
Country Status (13)
Country | Link |
---|---|
US (1) | US9963611B2 (en) |
EP (1) | EP2435139B1 (en) |
JP (1) | JP5740653B2 (en) |
KR (1) | KR101673044B1 (en) |
CN (1) | CN102448550B (en) |
AU (1) | AU2010254319B2 (en) |
BR (1) | BRPI1011482A2 (en) |
CA (1) | CA2761963C (en) |
IL (1) | IL216582A (en) |
MX (1) | MX347440B (en) |
MY (1) | MY188369A (en) |
SG (1) | SG176254A1 (en) |
WO (1) | WO2010138426A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012130117A1 (en) * | 2011-04-01 | 2012-10-04 | Filligent Limited | Mask structure for use in decreasing transmission of human pathogens |
EP2665526A1 (en) * | 2011-01-17 | 2013-11-27 | Royal Natural Medicine, S.R.O. | Face mask and method of its production |
WO2015162238A1 (en) * | 2014-04-24 | 2015-10-29 | Paul Boye Technologies | Mask having an outer surface made of nonwoven polypropylene impregnated with bronopol |
WO2015162243A1 (en) * | 2014-04-24 | 2015-10-29 | Paul Boye Technologies | Mask having an outer surface made of nonwoven polypropylene containing bronopol |
CN105286134A (en) * | 2015-12-07 | 2016-02-03 | 刘博纯 | Method for preparing photocatalytic mouth mask |
AU2015261574B2 (en) * | 2012-12-28 | 2018-01-18 | San-M Package Co., Ltd. | Mask |
US10660385B2 (en) | 2012-12-28 | 2020-05-26 | San-M Package Co., Ltd. | Mask |
WO2021001441A1 (en) * | 2019-07-01 | 2021-01-07 | Chemical Intelligence Limited | Antimicrobial dyes for facemasks |
WO2021195683A1 (en) * | 2020-04-01 | 2021-10-07 | Ess Holding Gmbh | Device for neutralizing inert and single-celled pathogens |
WO2022011111A1 (en) * | 2020-07-09 | 2022-01-13 | Vitiprints, LLC | Smart mask |
WO2022024049A1 (en) * | 2020-07-30 | 2022-02-03 | Fxi Inc. Limited | Coated substrates and articles with anti-viral properties |
EP3981252A1 (en) | 2020-10-07 | 2022-04-13 | Chemical Intelligence Limited | Antimicrobial facemask |
US12049095B2 (en) | 2019-07-01 | 2024-07-30 | Bmg (British Medical Group) Limited | Antimicrobial medical glove printing method |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11305082B2 (en) | 2008-05-29 | 2022-04-19 | Naturs Design, Inc. | Liner for use with respiratory mask |
US10071216B2 (en) | 2008-05-29 | 2018-09-11 | Naturs Design, Inc. | Liner for use with respiratory mask |
US9394637B2 (en) | 2012-12-13 | 2016-07-19 | Jacob Holm & Sons Ag | Method for production of a hydroentangled airlaid web and products obtained therefrom |
WO2014120492A1 (en) * | 2013-02-04 | 2014-08-07 | Naturs Design, Inc. | Liner for use with respiratory mask |
US9655392B2 (en) * | 2013-05-10 | 2017-05-23 | Jeffrey Mekler | Filtering face mask |
CN103952907A (en) * | 2014-05-17 | 2014-07-30 | 姚敏 | Composition for resisting pathogens, mask and manufacturing method of pathogen resisting layer of mask |
US20150335080A1 (en) * | 2014-05-23 | 2015-11-26 | Richard Giles | Face mask with adjustable earloops |
MA41021A (en) * | 2014-11-25 | 2017-10-03 | Cms Tech Inc | COPPER-BASED ANTIMICROBIAL COMPOSITIONS AND THEIR USE IN THE PROCESSING OF FOOD PRODUCTS AND SURFACES |
US10201198B2 (en) * | 2014-12-23 | 2019-02-12 | Profit Royal Pharmaceutical Limited | Protective masks with coating comprising different electrospun fibers interweaved with each other, formulations forming the same, and method of producing thereof |
US10357069B2 (en) * | 2016-06-20 | 2019-07-23 | Ronald Tuan | Gauze mask with folding lines capable of enabling the gauze mask to be folded into a flat package or unfolded into a three dimensional configuration |
US20190313716A1 (en) * | 2016-06-28 | 2019-10-17 | W. L. Gore & Associates Gmbh | Method for manufacturing a water vapor permeable or breathable three-dimensional glove or glove lining |
CN109562197B (en) * | 2016-08-19 | 2021-11-16 | 崔孝直 | Materials, devices and methods for inactivating pathogens in aerosols and methods for making the same |
USD849928S1 (en) * | 2017-05-15 | 2019-05-28 | Jonathan Grover | Facemask |
MX2020010074A (en) | 2018-03-27 | 2021-01-15 | Naturs Design Inc | Liner and retaining member for use with respiratory mask. |
US11857001B2 (en) | 2018-09-06 | 2024-01-02 | Sintx Technologies, Inc. | Antipathogenic face mask |
KR20210055735A (en) | 2018-09-06 | 2021-05-17 | 신티엑스 테크놀로지스, 잉크. | Antipathogenic composition and method thereof |
US20210282482A1 (en) * | 2020-03-16 | 2021-09-16 | QuShell LLC | Multifunctional face masks and fabricating methods and applications of same |
US11766079B2 (en) | 2020-03-30 | 2023-09-26 | Under Armour, Inc. | Face mask and method of making the same |
IT202000007186A1 (en) * | 2020-04-03 | 2021-10-03 | Cifra Spa | Facial mask and associated manufacturing process |
IT202000007195A1 (en) * | 2020-04-03 | 2021-10-03 | Stefano Sala | Antimicrobial device for masks |
WO2021211697A1 (en) * | 2020-04-14 | 2021-10-21 | Sintx Technologies, Inc. | Antipathogenic face mask |
US11178923B1 (en) * | 2020-05-08 | 2021-11-23 | Virothera Pharmaceuticals LLC | Environmentally natural protective and therapeutic (ENPT) face mask |
US10966471B1 (en) * | 2020-05-19 | 2021-04-06 | Aslan Medical Equipment, Llc | Soft silicon edged cushion for face masks |
US11033060B1 (en) | 2020-05-19 | 2021-06-15 | Aslan Medical Equipment, Llc | Soft silicone edged cushion for face and oxygen masks with ultraviolet light source |
EP4153418A1 (en) * | 2020-05-21 | 2023-03-29 | X Cell, LLC | Apparatus and method to provide single-ply pathogenicidal barrier between first and second regions |
USD1010938S1 (en) * | 2020-05-26 | 2024-01-09 | Tiffany Du | Face mask with two inner compartments |
WO2021243475A1 (en) * | 2020-06-03 | 2021-12-09 | Solubag Spa | Disposable cloth mask, water-soluble in hot water, for the elimination of pathogens |
US11284654B2 (en) | 2020-06-10 | 2022-03-29 | Under Armour, Inc. | Breathable face mask |
KR102319112B1 (en) * | 2020-08-31 | 2021-10-29 | (주)한경컴퍼니 | Mask having droplet penetration proofing |
JP1705182S (en) * | 2020-09-07 | 2022-01-17 | mask | |
US11064745B1 (en) * | 2020-11-12 | 2021-07-20 | United Arab Emirates University | Face mask with separate inhaling and exhaling portions |
USD1004073S1 (en) | 2021-03-04 | 2023-11-07 | Devarati Roy | Mask |
USD1000603S1 (en) | 2021-03-04 | 2023-10-03 | Devarati Roy | Mask |
WO2022202660A1 (en) * | 2021-03-25 | 2022-09-29 | 三菱ケミカル株式会社 | Resin composition, coating solution, film, and multilayer structure |
JP1705581S (en) | 2021-05-17 | 2022-01-20 | Mask body | |
US20230109115A1 (en) * | 2021-10-04 | 2023-04-06 | Livinguard Ag | Wash-durable and reusable respiratory face mask |
US20230111665A1 (en) * | 2021-10-13 | 2023-04-13 | Veronica Deloach | Face mask device |
USD1028783S1 (en) * | 2021-12-02 | 2024-05-28 | Curiosity Gardens Llc | Memorial mask pendant |
US11812737B1 (en) * | 2022-08-03 | 2023-11-14 | Darren Mark Teren | Wearable protection device for residential and commercial trash cans and method of use |
US11672245B1 (en) * | 2022-08-03 | 2023-06-13 | Darren Mark Teren | Pest control device for residential trash cans and method of use |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040255946A1 (en) * | 2002-06-05 | 2004-12-23 | Gerson Ronald L. | Stiffened filter mask |
US20060198903A1 (en) * | 2002-12-18 | 2006-09-07 | Storey Daniel M | Antimicrobial coating methods |
WO2008009651A1 (en) * | 2006-07-18 | 2008-01-24 | Glaxo Group Limited | Anti-viral face mask and filter material |
WO2008118371A2 (en) * | 2007-03-22 | 2008-10-02 | Mvp Textiles & Apparel, Inc. | Antimicrobial filtration article |
US20090035390A1 (en) * | 2006-01-06 | 2009-02-05 | Modak Shanta M | Compositions containing zinc salts for coating medical articles |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3603444A1 (en) * | 1986-02-05 | 1987-08-06 | Thomae Gmbh Dr K | PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA |
JPH05139955A (en) * | 1991-11-21 | 1993-06-08 | Lion Corp | Stable instillation |
US5467765A (en) * | 1994-10-06 | 1995-11-21 | Maturaporn; Thawatchai | Disposable face mask with multiple liquid resistant layers |
JP2868206B2 (en) * | 1996-04-16 | 1999-03-10 | 株式会社オフテクス | Composition for controlling harmful microorganisms for disinfection and / or preservation |
JP3765147B2 (en) * | 1997-02-17 | 2006-04-12 | 東レ株式会社 | Deodorant molded product and method for producing the same |
US5883026A (en) * | 1997-02-27 | 1999-03-16 | Kimberly-Clark Worldwide, Inc. | Face masks including a spunbonded/meltblown/spunbonded laminate |
JP2002104911A (en) * | 2000-09-28 | 2002-04-10 | Iwata Shingu Kk | Plant extract formulation liquid agent composition and fiber containing the same |
AU2002233940A1 (en) * | 2000-11-27 | 2002-06-03 | Kimberly-Clark Worldwide, Inc. | Face mask filtration media with improved breathability |
US7563461B2 (en) * | 2002-02-07 | 2009-07-21 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
US20040000313A1 (en) * | 2002-06-28 | 2004-01-01 | Kimberly-Clark Worldwide, Inc. | Spunbonded/meltblown/spunbonded laminate face mask |
EP1571904A2 (en) * | 2002-12-18 | 2005-09-14 | Ionic Fusion Corporartion | Ionic plasma deposition of anti-microbial surfaces and the anti-microbial surfaces resulting therefrom |
JP3100614U (en) * | 2003-09-24 | 2004-05-27 | ダイヤ製薬株式会社 | mask |
JP4864376B2 (en) * | 2005-08-08 | 2012-02-01 | 玉川衛材株式会社 | mask |
JP2007054381A (en) * | 2005-08-25 | 2007-03-08 | Kurashiki Seni Kako Kk | Cubical mask |
CN101454406B (en) * | 2006-02-23 | 2013-03-27 | 纳幕尔杜邦公司 | Removable antimicrobial coating compositions and methods of use |
EP2034831A2 (en) * | 2006-05-31 | 2009-03-18 | The Dial Corporation | Alcohol-containing antimicrobial compositions having improved efficacy |
US20080207774A1 (en) * | 2006-08-24 | 2008-08-28 | Venkataram Krishnan | Anionic latex as a carrier for active ingredients and methods for making and using the same |
NZ582753A (en) * | 2007-06-26 | 2012-06-29 | Filligent Ltd | Devices and methods for decreasing human pathogen transmission |
-
2010
- 2010-05-21 MX MX2011012545A patent/MX347440B/en active IP Right Grant
- 2010-05-21 US US13/319,836 patent/US9963611B2/en active Active - Reinstated
- 2010-05-21 SG SG2011087541A patent/SG176254A1/en unknown
- 2010-05-21 MY MYPI2011005730A patent/MY188369A/en unknown
- 2010-05-21 BR BRPI1011482A patent/BRPI1011482A2/en not_active IP Right Cessation
- 2010-05-21 CN CN201080023681.3A patent/CN102448550B/en active Active
- 2010-05-21 CA CA2761963A patent/CA2761963C/en active Active
- 2010-05-21 EP EP10781047.5A patent/EP2435139B1/en active Active
- 2010-05-21 KR KR1020117031441A patent/KR101673044B1/en active IP Right Grant
- 2010-05-21 AU AU2010254319A patent/AU2010254319B2/en active Active
- 2010-05-21 WO PCT/US2010/035864 patent/WO2010138426A1/en active Application Filing
- 2010-05-21 JP JP2012513146A patent/JP5740653B2/en active Active
-
2011
- 2011-11-24 IL IL216582A patent/IL216582A/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040255946A1 (en) * | 2002-06-05 | 2004-12-23 | Gerson Ronald L. | Stiffened filter mask |
US20060198903A1 (en) * | 2002-12-18 | 2006-09-07 | Storey Daniel M | Antimicrobial coating methods |
US20090035390A1 (en) * | 2006-01-06 | 2009-02-05 | Modak Shanta M | Compositions containing zinc salts for coating medical articles |
WO2008009651A1 (en) * | 2006-07-18 | 2008-01-24 | Glaxo Group Limited | Anti-viral face mask and filter material |
WO2008118371A2 (en) * | 2007-03-22 | 2008-10-02 | Mvp Textiles & Apparel, Inc. | Antimicrobial filtration article |
Non-Patent Citations (1)
Title |
---|
See also references of EP2435139A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2665526A1 (en) * | 2011-01-17 | 2013-11-27 | Royal Natural Medicine, S.R.O. | Face mask and method of its production |
WO2012130117A1 (en) * | 2011-04-01 | 2012-10-04 | Filligent Limited | Mask structure for use in decreasing transmission of human pathogens |
AU2015261574B2 (en) * | 2012-12-28 | 2018-01-18 | San-M Package Co., Ltd. | Mask |
US10660385B2 (en) | 2012-12-28 | 2020-05-26 | San-M Package Co., Ltd. | Mask |
WO2015162238A1 (en) * | 2014-04-24 | 2015-10-29 | Paul Boye Technologies | Mask having an outer surface made of nonwoven polypropylene impregnated with bronopol |
WO2015162243A1 (en) * | 2014-04-24 | 2015-10-29 | Paul Boye Technologies | Mask having an outer surface made of nonwoven polypropylene containing bronopol |
FR3020245A1 (en) * | 2014-04-24 | 2015-10-30 | Paul Boye Technologies | NON-WOVEN POLYPROPYLENE EXTERNAL FACE MASK IMPREGNATED WITH BRONOPOL |
FR3020246A1 (en) * | 2014-04-24 | 2015-10-30 | Paul Boye Technologies | NON-WOVEN POLYPROPYLENE EXTERNAL FACE MASK COMPRISING BRONOPOL |
CN105286134A (en) * | 2015-12-07 | 2016-02-03 | 刘博纯 | Method for preparing photocatalytic mouth mask |
CN114375317A (en) * | 2019-07-01 | 2022-04-19 | 化学智能公司 | Antimicrobial dye for mask |
WO2021001441A1 (en) * | 2019-07-01 | 2021-01-07 | Chemical Intelligence Limited | Antimicrobial dyes for facemasks |
US12049095B2 (en) | 2019-07-01 | 2024-07-30 | Bmg (British Medical Group) Limited | Antimicrobial medical glove printing method |
WO2021195683A1 (en) * | 2020-04-01 | 2021-10-07 | Ess Holding Gmbh | Device for neutralizing inert and single-celled pathogens |
WO2022011111A1 (en) * | 2020-07-09 | 2022-01-13 | Vitiprints, LLC | Smart mask |
TWI809436B (en) * | 2020-07-09 | 2023-07-21 | 美商維提印刷有限責任公司 | Smart mask |
US11937653B2 (en) | 2020-07-09 | 2024-03-26 | Vitiprints, LLC | Smart mask |
WO2022024049A1 (en) * | 2020-07-30 | 2022-02-03 | Fxi Inc. Limited | Coated substrates and articles with anti-viral properties |
US11678703B2 (en) | 2020-07-30 | 2023-06-20 | Fxi Inc. Limited | Coated substrates and articles with anti-viral properties, and fabrication processes |
US11930867B2 (en) | 2020-07-30 | 2024-03-19 | Fxi Inc. Limited | Coated substrates and articles with anti-viral properties, and fabrication processes |
EP3981252A1 (en) | 2020-10-07 | 2022-04-13 | Chemical Intelligence Limited | Antimicrobial facemask |
WO2022074384A1 (en) | 2020-10-07 | 2022-04-14 | Chemical Intelligence Limited | Antimicrobial facemask |
Also Published As
Publication number | Publication date |
---|---|
KR20120065278A (en) | 2012-06-20 |
CA2761963C (en) | 2018-03-20 |
IL216582A0 (en) | 2012-02-29 |
EP2435139B1 (en) | 2016-10-05 |
CA2761963A1 (en) | 2010-12-02 |
EP2435139A1 (en) | 2012-04-04 |
JP2012528255A (en) | 2012-11-12 |
BRPI1011482A2 (en) | 2016-03-22 |
US20120060258A1 (en) | 2012-03-15 |
MX347440B (en) | 2017-04-26 |
SG176254A1 (en) | 2011-12-29 |
CN102448550A (en) | 2012-05-09 |
JP5740653B2 (en) | 2015-06-24 |
KR101673044B1 (en) | 2016-11-04 |
US9963611B2 (en) | 2018-05-08 |
CN102448550B (en) | 2016-06-15 |
MX2011012545A (en) | 2012-02-28 |
AU2010254319A1 (en) | 2011-11-24 |
AU2010254319B2 (en) | 2016-03-10 |
MY188369A (en) | 2021-12-06 |
IL216582A (en) | 2016-04-21 |
EP2435139A4 (en) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010254319B2 (en) | Composition for use in decreasing the transmission of human pathogens | |
US8678002B2 (en) | Devices and methods for decreasing human pathogen transmission | |
WO2009146412A1 (en) | Protective face mask | |
US9901128B2 (en) | Antimicrobial apparel and fabric and coverings | |
US20110110818A1 (en) | Dry sanitizing patch for decreasing human pathogen transmission | |
US10182946B2 (en) | Advanced fabric technology and filters | |
KR20090036136A (en) | Anti-viral face mask and filter material | |
US20080289088A1 (en) | N-alkylchitosan films and laminates made therefrom | |
US20210282482A1 (en) | Multifunctional face masks and fabricating methods and applications of same | |
US20220298674A1 (en) | Active apparel and fabric and coverings | |
JP2021169688A (en) | mask |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080023681.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10781047 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 13319836 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8831/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2761963 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2010254319 Country of ref document: AU Date of ref document: 20100521 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/012545 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012513146 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010781047 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010781047 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117031441 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1011482 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1011482 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111129 |